were living apart from their husbands, and one was a widow. Females born in Great Britain accounted for 74 per cent. of the cases, fifteen were from Southern Ireland, seven were West Indians, and one was from India.
. Of these thirteen patients, five were in the "cured" category, seven "improved", and one "unchanged" (Table I ). The number of follow-up examinations carried out and the times at which the parasite was recovered are shown in Table II . (Table II) . This is a difficult question to decide. Generally speaking the longer the interval,between treatment and the reappearance of infection, the more likely is this to be due to reinfection. It would seem likely that the two cases in this trial in which vaginitis recurred 7 weeks and 9 weeks after treatment were re-infections, and possible that those in which the parasite reappeared within 2 or 3 weeks after treatment were relapses.
It was our clinical impression that the acute signs of trichomonal vaginitis cleared less quickly and less frequently with Magmilor than with Flagyl and that recurrences were more common after Magmilor than after Flagyl. As seen in Tables III and IV , the findings from the 96 patients treated with Flagyl support our clinical impressions. It will be noted that there were only three recurrences after Flagyl (Table IV) compared with fifteen after Magmilor (Table II) . As the male consorts of both Magmilor and Flagyl patients were all treated with Flagyl, the lower recurrence rate in the Flagyl group cannot be attributed to more effective treatment of the male partner and it would seem likely that at least the earlier recurrences after Magmilor therapy were relapses rather than re-infections. This might indicate that the recommended dosage of Magmilor is inadequate and should be increased. (The absence of any adverse reactions in the present trial suggests that an increase in dosage might be possible.)
However, whether or not it is possible to give larger amounts of Magmilor, it has been found in this trial that with the present treatment schedule Magmilor will cure at least 65*7 per cent. of patients. Magmilor may not be quite so spectacular a therapy as Flagyl, but a study of the results obtained by Willcox (1957) 
